Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Nederland
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Nieuws
  7. Andere talen
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Rapport
Real Time Euronext Amsterdam  -  15:25:21 02-02-2023
40.28 EUR   +1.08%
23/01Galapagos NV : Jefferies & Co. herziet advies naar Neutraal
MM
23/01Jefferies haalt Galapagos van verkooplijst
AM
10/01Galapagos ontvangt transparantieverklaring van FMR LLC
GL
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Nieuws in andere talen op GALAPAGOS NV
23/01Avis d'analystes du jour : Sartorius Stedim Biotech, Unibail, R..
19/01Galapagos : J.P. Morgan Healthcare Conference January 9, 2023 - Form 6-K
10/01Galapagos receives transparency notification from FMR LLC
10/01Galapagos receives transparency notification from FMR LLC
03/01Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
03/01Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos receives transparency notification from FMR LLC
2022Bolsa de Madrid: Todavía en modo ciclotímico
2022Toujours en mode cyclothymique
2022En Direct des Marchés : Stellantis, GTT, Valneva, BHP, Tesla, Meta..
2022Belgian Biotech Galapagos' Chief Medical Officer, Chief Business Officer To Step Down a..
2022Galapagos announces changes to Executive Committee
2022Galapagos announces changes to Executive Committee
2022Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023
2022GALAPAGOS : la biotech belge cherche un rival à acheter
2022Belgian Biotech Galapagos Eyes Purchase of Early-stage Drugmakers in Europe, CEO Says
2022Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a ..
2022Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a ..
2022Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a C..
2022European Medicines Agency Panel Adopts Recommendation for Galapagos' Jyseleca Product L..
2022Galapagos announces CHMP adoption of PRAC's recommendation for Jyselecaģ following exte..
2022Galapagos announces CHMP adoption of PRAC's recommendation for Jyselecaģ following exte..
2022Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyselecaģ Following..
2022Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study..
2022Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study..
2022Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis st..
2022Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
2022Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
2022Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
2022Galapagos announces strategy to accelerate innovation and reports strong third quarter ..
2022Galapagos NV Reports Earnings Results for the Nine Months Ended September 30, 2022
2022Galapagos : Press release dated October 17, 2022 - Form 6-K
2022Galapagos to host its R&D Update 2022 in New York on 4 November 2022
2022Galapagos to host its R&D Update 2022 in New York on 4 November 2022
2022Galapagos to Present Data on Prospective Ulcerative Colitis Treatment at Upcoming Confe..
2022Galapagos provides further insights into the treatment of ulcerative colitis at the upc..
2022Galapagos provides further insights into the treatment of ulcerative colitis at the upc..
2022Galapagos Says It Secured Positive Regulatory Opinion on Jyseleca's European Label Upda..
2022Galapagos Wins EU Health Agency Backing To Remove Male Fertility Warning On Jyseleca's ..
2022Galapagos NV Says It Secures Positive Regulatory Opinion on Jyseleca's European Label U..
2022Galapagos receives positive CHMP opinion for Jyselecaģ European label update based on t..
2022Galapagos receives positive CHMP opinion for Jyselecaģ European label update based on t..
2022Galapagos Receives Positive CHMP Opinion for Jyselecaģ European Label Update Based on T..
2022Galapagos increases share capital through subscription right exercises
2022Galapagos increases share capital through subscription right exercises
2022Galapagos NV announced that it has received €3.07625 million in funding
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos to present at upcoming investor conferences
2022Galapagos to present at upcoming investor conferences
2022Galapagos : receives transparency notification from FMR LLC - Form 6-K
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos : receives transparency notification from FMR LLC - Form 6-K
2022Galapagos : First key steps in pipeline rebuild and strong commercial progress in H1 2022 ..
2022Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos Q2 Loss Narrows as Net Revenue Falls
2022First key steps in pipeline rebuild and strong commercial progress in H1 2022
2022Galapagos NV Reports Earnings Results for the Half Year Ended June 30, 2022
2022Actualización de las fuertes variaciones del día: L..
2022Point sur les fortes variations du jour : début de ..
2022Bolsa de Madrid: Embotellamientos de verano
2022Embouteillages estivaux
2022Avis d'analystes du jour : BNP Paribas, Adecco, Ubisoft, UCB, C..
2022Galapagos : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
2022Galapagos : increases share capital through subscription right exercises - Form 6-K
2022Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2..
2022Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions
2022Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
2022Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
2022Galapagos NV acquired CellPoint B.V. from ND Capital and others for approximately €..
2022Galapagos NV acquired Abound Bio, Inc. for $14 million.
2022Galapagos increases share capital through subscription right exercises
2022Galapagos increases share capital through subscription right exercises
2022Galapagos NV announced that it expects to receive €1.459507 million in funding
2022Galapagos : receives transparency notification from FMR LLC - Form 6-K
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos receives transparency notification from FMR LLC
2022Galapagos : to showcase commitment to rheumatoid arthritis care at the upcoming European L..
2022Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European ..
2022Galapagos In-Licenses Drug Targets for Inflammatory Bowel Disease From Scipher
2022Intervest Offices & Warehouses Extends Lease Deals For Office Portfolio In Belgium
2022Galapagos creates new subscription right plans
2022Galapagos creates new subscription right plans
2022Galapagos demonstrates regulatory and commercial progress in Q1 2022
2022Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Galapagos NV Declares Voting Results
2022Galapagos : announces appointment of Dr. Paul Stoffels as Chairman of the board - Form 6-K
2022Galapagos Names CEO As Chairman Under New Governance Structure
2022Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
2022Galapagos NV Announces Executive Appointments
2022E-therapeutics Achieves Key Milestones Under Collaboration with Galapagos
2022E-therapeutics plc Announces A Key Milestone in Its Collaboration with Galapagos
2022Subject : Galapagos AGM/EGM 2022 April 11th, 2022 - Form 6-K
2022Galapagos : Chairman letter to shareholders
2022Galapagos : Glpg egm & agm 2022
2022Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION ..
Volgende evenement op GALAPAGOS NV